FDA Grants Orphan Drug Designation to MAIA Biotechnology for THIO as a Treatment for GlioblastomaBusiness Wire • 11/10/23
MAIA Biotechnology Reports Third Quarter 2023 Financial Results and Highlights Recent Development Progress for Anticancer Asset THIOBusiness Wire • 11/07/23
MAIA Biotechnology Reports Positive Phase 2 Clinical Trial Data On Its Treatment For Non-Small Cell Lung CancerAccesswire • 10/31/23
MAIA Biotechnology Reveals Higher Anticancer Potency of Telomere-Targeting Compounds Derived from THIOBusiness Wire • 10/30/23
MAIA Biotechnology Announces 100% Disease Control in Second-Line Non-Small Cell Lung Cancer Demonstrating Impressive Positive Preliminary Efficacy Data for Ongoing THIO-101 Phase 2 TrialBusiness Wire • 10/24/23
MAIA Biotechnology to Present Preliminary Safety and Efficacy Data from THIO-101 Phase 2 Clinical Trial at European Society for Medical Oncology Congress 2023Business Wire • 10/19/23
MAIA Biotechnology's THIO Emerges As Potential Breakthrough In Pediatric Brain Cancer TherapyAccesswire • 10/17/23
MAIA Biotechnology to Present Latest Findings for Second Generation THIO Program at Turkish Biochemical Society's International Biochemistry Congress 2023Business Wire • 10/17/23
MAIA Biotechnology Reveals New Data Showing THIO's Potent Anticancer Activity in Aggressive Pediatric Brain CancerBusiness Wire • 10/12/23
MAIA Biotechnology Accelerates Enrollment in THIO-101 Phase II Clinical Trial as Efficacy Is Observed in Dosed PatientsBusiness Wire • 10/10/23
MAIA Biotechnology Announces FDA Clearance of IND Application for THIO, a First-in-Class Telomere Targeting Agent for the Treatment of Non-Small Cell Lung CancerBusiness Wire • 10/03/23
MAIA Biotechnology, Inc. (MAIA) Could Find a Support Soon, Here's Why You Should Buy the Stock NowZacks Investment Research • 08/21/23
MAIA Biotechnology Reports Second Quarter 2023 Financial Results and Provides Updates for THIO-101 Phase 2 Trial for Non-Small Cell Lung CancerBusiness Wire • 08/08/23
MAIA Biotechnology Reports Updates on Disease Control Rates for THIO-101 Phase 2 Trial for Advanced Non-Small Cell Lung CancerBusiness Wire • 07/11/23
MAIA Biotechnology Reports Updates on Preliminary Survival Data for THIO-101 Phase 2 Trial for Advanced Non-Small Cell Lung CancerBusiness Wire • 07/10/23
MAIA Biotechnology Announces Updates in Enrollment in Phase II Clinical Trial: THIO-101 Has Enrolled 29 PatientsBusiness Wire • 06/20/23
MAIA Biotechnology Files Second Patent For New Telomere-Targeting Molecules ProgramBusiness Wire • 06/07/23
MAIA Biotechnology Reports First Quarter 2023 Financial Results and Provides Corporate UpdateBusiness Wire • 05/08/23
MAIA Biotechnology Reports Preliminary Survival Data in Part A of THIO-101 Phase 2 Trial for Non-Small Cell Lung CancerBusiness Wire • 04/20/23